Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Venous thromboembolism prophylaxis of a patient with MYH-9 related disease and COVID-19 infection: A case report
Bei Jiang, Muhammad Masab, Laurel Lyckholm, Department of Hematology and Oncology, West Virginia University, Morgantown, WV 26505, United States
Michelle Hartzell, Stephen Yu, Department of Internal Medicine, West Virginia University, Morgantown, WV 26505, United States
Author contributions: All authors contributed equally; all authors conceptualized the manuscript; Jiang B wrote the initial manuscript; Jiang B, Hartzell M, Yu S and Masab M edited and conducted the literature research; Lyckholm L edited and critically corrected and finalized the manuscript; Jiang B, Hartzell M and Lyckholm L were directly involved in the patient management.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bei Jiang, MD, Doctor, Department of Hematology and Oncology, West Virginia University, 1 Medical Drive, Morgantown, WV 26505, United States.
Received: July 22, 2022
Peer-review started: July 22, 2022
First decision: September 26, 2022
Revised: October 6, 2022
Accepted: December 6, 2022
Article in press: December 6, 2022
Published online: January 5, 2023
Processing time: 165 Days and 17.1 Hours
Peer-review started: July 22, 2022
First decision: September 26, 2022
Revised: October 6, 2022
Accepted: December 6, 2022
Article in press: December 6, 2022
Published online: January 5, 2023
Processing time: 165 Days and 17.1 Hours
Core Tip
Core Tip: May-Hegglin anomaly is one of several autosomal dominant disorders described as MYH9 mutation-related diseases (MYH9-RD). A mutation in the MYH9 gene causes macrothrombocytopenia and a mild to moderate bleeding tendency. Severity of bleeding in patients with MYH9-RD is related to the degree of thrombocytopenia and to physical properties of the large platelets. MYH9-RD is not an absolute contraindication to anticoagulation or antiplatelet agents. If a patient with MYH9-RD presents with an indication for anticoagulation, such as coronavirus disease 2019 infection, one must take a careful history of previous bleeding episodes and weigh bleeding risk against the risk of thrombosis.